Please ensure Javascript is enabled for purposes of website accessibility

Got $100? These 2 Robinhood Stocks Are Great Picks to Buy Right Now

By Keith Speights - Jun 5, 2021 at 6:01AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

You can scoop up both of these solid stocks and still have a little money left over.

When is the best time to start investing? Now. Trading platforms such as Robinhood make it easy to begin investing and don't charge a commission. All you need is some money to get started.

Robinhood even provides a list of the 100 most popular stocks among investors on the platform, which can give you some ideas for where to invest. And you won't need much money to scoop up shares of some of them. If you've got $100, these two Robinhood stocks are great picks to buy right now.

Smiling person holding a $100 bill

Image source: Getty Images.

Bank of America

You can currently buy a share of Bank of America (BAC 0.45%) for less than $44. It's the most widely held bank stock among Robinhood investors. It's also Warren Buffett's favorite bank stock.

Don't buy Bank of America just because others like it, though. There are several reasons why the stock is a good choice right now.

For one thing, interest rates are bound to increase in the not-too-distant future. The Federal Reserve Board won't be able to keep rates as low as they are now indefinitely, especially with inflation becoming more of an issue. Bank of America will directly benefit if and when interest rates rise.

A rebounding global economy should also boost the company's fortunes. Increased availability of COVID-19 vaccines has already made a huge difference in the U.S. and hopefully will do so throughout the rest of the world in the coming months. The prospects of a massive infrastructure bill could also fuel a stronger economic recovery. All of this adds up to more lending, which is music to the ears of Bank of America.

Of course, rising interest rates and an improving economy should help most bank stocks. What makes Bank of America stand out from the pack? I'd put diversification of revenue near the top of the list. The financial services giant makes money in multiple ways, including consumer banking, investment banking, and wealth and investment management.

I also like Bank of America's focus on technological innovation. The company has received numerous awards for its digital solutions. It's not just getting accolades from other organizations, though -- Bank of America's customers have significantly increased their usage of the bank's digital products.


Pfizer (PFE 0.34%) currently trades at less than $40 per share. After buying one share of Bank of America, you'd still have enough of your initial $100 to pick up a share of the big drugmaker and still have money left over. Pfizer stands out as one of the very few stocks that could be attractive to growth, income, and value investors.  

The company reported 42% year-over-year revenue growth in the first quarter. Earnings soared 44%. Some of this growth was because Pfizer no longer has older drugs that have lost exclusivity weighing it down. Those drugs are now in Viatris' lineup. Viatris was formed in November 2020 with the merger of Mylan with Pfizer's former Upjohn unit.

However, the main growth driver for Pfizer is its COVID-19 vaccine. Sales for the vaccine totaled nearly $3.5 billion in Q1. Pfizer looks for the vaccine to rake in sales of $26 billion this year, and it could generate strong recurring revenue for a long time to come. CEO Albert Bourla predicted last month that "a durable demand from our COVID-19 vaccine, similar to that of the flu vaccines, is a likely outcome."

Income investors will almost certainly like Pfizer's dividend yield of more than 4%. Pfizer had initially expected to cut the dividend once Viatris initiated its own dividend program, but the huge influx of cash from COVID-19 vaccine sales allowed the company to keep its dividend payout unchanged.

You might think that Pfizer, with its strong growth and juicy dividend, would be priced at a premium valuation. That isn't the case. The big pharma stock trades at less than 12 times expected earnings. 

Now's the time

My view is that $100 won't be enough to buy shares of both Pfizer and Bank of America for too much longer. If I'm right, the best time to invest in these two popular Robinhood stocks truly is right now. 

Bank of America is an advertising partner of The Ascent, a Motley Fool company. Keith Speights owns shares of Bank of America, Pfizer, and Viatris Inc. The Motley Fool recommends Viatris Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
$49.74 (0.34%) $0.17
Bank of America Corporation Stock Quote
Bank of America Corporation
$33.64 (0.45%) $0.15
Viatris Inc. Stock Quote
Viatris Inc.
$10.04 (-0.45%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.